{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:52:56Z","timestamp":1795027976545,"version":"4.10.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01469-z","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:44:34Z","timestamp":1774028674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed\/refractory multiple myeloma (RRMM)\u2014real world experience from the US multiple myeloma immunotherapy consortium"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8066-6781","authenticated-orcid":false,"given":"Cindy","family":"Varga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-0781","authenticated-orcid":false,"given":"Charlotte B.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeunia","family":"Bhurtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"given":"Larry D.","family":"Anderson Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4292","authenticated-orcid":false,"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5462-4991","authenticated-orcid":false,"given":"Alex","family":"Lieberman-Cribbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sherbenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Purvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kocoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-5507","authenticated-orcid":false,"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-4856","authenticated-orcid":false,"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"1469_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397.","journal-title":"Blood"},{"key":"1469_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1469_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"1469_CR4","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776\u201387.","journal-title":"Blood Adv"},{"key":"1469_CR5","doi-asserted-by":"crossref","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol. 2025:JCO2401730.","DOI":"10.1016\/S2152-2650(24)01848-2"},{"key":"1469_CR6","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022;6:6109\u201319.","journal-title":"Blood Adv"},{"key":"1469_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865\u201377.","journal-title":"Blood"},{"key":"1469_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood.2025028833","volume":"146","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, et al. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025;146:834\u201346.","journal-title":"Blood"},{"key":"1469_CR9","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","volume":"6","author":"KR Juluri","year":"2022","unstructured":"Juluri KR, Wu QV, Voutsinas J, Hou J, Hirayama AV, Mullane E, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022;6:2055\u201368.","journal-title":"Blood Adv"},{"key":"1469_CR10","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood.2022017015","volume":"140","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Wu Z, Blumenberg V, Kunz WG, Muller S, Kajigaya S, et al. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL. Blood. 2022;140:2175\u20139.","journal-title":"Blood"},{"key":"1469_CR11","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460\u20139.","journal-title":"Blood"},{"key":"1469_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transpl. 2020;26:26\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1469_CR13","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513.","journal-title":"Blood"},{"key":"1469_CR14","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1469_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1159\/000538047","volume":"147","author":"AD Heini","year":"2024","unstructured":"Heini AD, Bacher VU, Akhoundova D, Seipel K, Pabst T. Peeling back the layers: recurrent talquetamab skin toxicity after supportive stem cell boost in multiple myeloma. Acta Haematol. 2024;147:729\u201334.","journal-title":"Acta Haematol"},{"key":"1469_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","volume":"29","author":"JA Davis","year":"2023","unstructured":"Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transplant Cell Ther. 2023;29:567\u201371.","journal-title":"Transplant Cell Ther"},{"key":"1469_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","volume":"59","author":"M Mohan","year":"2024","unstructured":"Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024;59:647\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"1469_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2024-210725","volume":"144","author":"K Yadav","year":"2024","unstructured":"Yadav K, Patel TH, Bachu R, Esselmann J, Rein LE, Szabo A, et al. Application of stem cell boost for immune effector cell associated hematotoxicity (ICAHT) following BCMA directed chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM). Blood. 2024;144:254.","journal-title":"Blood"},{"key":"1469_CR19","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/bloodadvances.2025016346","volume":"9","author":"S Ananth","year":"2025","unstructured":"Ananth S, Torres NE, Sahaf B, Mikkilineni L, Fernandez-Pol S, Salmi D, et al. Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy. Blood Adv. 2025;9:3832\u20136.","journal-title":"Blood Adv"},{"key":"1469_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1469_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14:63.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01469-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01469-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01469-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:01:04Z","timestamp":1774458064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01469-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01469-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CV reports research funding from Janssen, Kite Pharma, K36 Therapeutics, Arcellx; consulting or advisory role for Janssen. JAD reports consulting or advisory role for Janssen. HH reports consulting or advisory role for Janssen, Amgen, and Karyopharm. TGM reports receiving research funding from Sanofi, Amgen, and Janssen Oncology, and serving as a consultant or in an advisory role for GlaxoSmithKline and Legend Biotech. AK reports research funding from Bristol Myers Squibb and AstraZeneca. DWS reports serving in an advisory role or as consultant for Janssen, Bristol Myers Squibb, GlaxoSmithKline, Sanofi, Legend Biotech, Opna Bio, Pfizer, AbbVie, AstraZeneca, and Genentech, and receiving research support from Pfizer. CBW Pfizer: Consultancy; Jazz: Research Funding. DKH reports research funding from Bristol-Myers Squibb, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting or advisory role for Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma, and Karyopharm. O.C.P. reports serving as a consultant or in an advisory role for Bristol Myers Squibb, Janssen, and Legend Biotech. L.S. reports serving as a consultant for Bristol Myers Squibb. AA reports research funding from Abbvie, Adaptive Biotech, K36 Therapeutics, Janssen, Regeneron; Consulting or advisory role for Karyopharm, Bristol Myers Squibb, Janssen, Pfizer and Sanofi. LDA Jr reports research funding from Bristol Myers Squibb, AbbVie, Janssen, and Cellectar; and consulting or serving in an advisory role for or receiving honoraria from Celgene, Janssen, Amgen, Bristol Myers Squibb, GSK, AbbVie, BeiGene, Cellectar, Sanofi, Karyopharm, Pfizer, and Prothena. BD reports serving as a consultant or in advisory role for Bristol Myers Squibb, Janssen, Genentech, Kite Pharma, Pfizer, Arcellx, Karyopharm, ECor1, Takeda, and Natera, and receiving research funding from Bristol Myers Squibb, Janssen, Arcellx, CARsgen, C4 Therapeutics, and Sanofi. SR reports serving as a consultant for Pfizer and Prothena Biosciences and receiving research funding from Nexcella Inc, Poseida Therapeutics, and Janssen. DS Sanofi: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; Jansen: Membership on an entity\u2019s Board of Directors or advisory committees. PAF reports serving as a consultant for Janssen and Sanofi and receiving research funding from Karyopharm. JK reports serving as a consultant for GPCR Therapeutics, Janssen, Prothena, and Legend Biotech, and receiving research funding from Prothena, Ascentage, Janssen, Karyopharm, and GPCR Therapeutics. YL reports serving as a consultant for Janssen, Legend, Celgene, Sanofi, Bristol Myers Squibb, Pfizer, Regeneron, Genentech, NexImmune, and Caribou Biosciences, and receiving research funding from Janssen, Celgene, and Bristol Myers Squibb. SS reports receiving research support from Magenta Therapeutics, Bristol Myers Squibb, Allogene, Janssen, Novartis, and AbbVie, and serving on the advisory board or as a consultant for Bristol Myers Squibb, Janssen, Sanofi, Oncopeptides, Takeda, Regeneron, AbbVie, Pfizer, BioLineRx, Legend, and Kite Pharma. KKP reports serving as a consultant for Bristol Myers Squibb, Janssen, AstraZeneca, Legend Biotech, Kite Pharma, Genentech, AbbVie, Sanofi, Caribou Biosciences, Takeda, Regeneron, and Poseida. SM reports serving as a consultant for Janssen and Pfizer; receiving honoraria from Pfizer; and owning stock in AbbVie. CJF reports consulting or advisory role for Janssen, research funding from Janssen and Regeneron. Remaining authors with no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}